| 0.012 -0.007 (-36.84%) | 12-18 12:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.04 | 1-year : | 0.06 |
| Resists | First : | 0.03 | Second : | 0.05 |
| Pivot price | 0.02  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.01  |
MA(20) : | 0.03 |
| MA(100) : | 0.03 |
MA(250) : | 0.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.5 |
D(3) : | 13 |
| RSI | RSI(14): 27.7 |
|||
| 52-week | High : | 0.1 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLPH ] has closed above bottom band by 21.1%. Bollinger Bands are 354.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Tue, 25 Jul 2023
Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts - InvestorPlace
Mon, 05 Jun 2023
PLTR Stock Alert: Palantir Lands New Contract With U.S. Special Ops - InvestorPlace
Fri, 31 Mar 2023
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results - citybiz
Wed, 26 May 2021
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors - citybiz
Mon, 01 Feb 2021
7 notable pulmonary fibrosis research efforts - drugdiscoverytrends.com
Wed, 22 Aug 2018
As Nitric Oxide Comes Off Patent Lower-Cost Options for Life Saving Drug Becoming Possible - streetwisereports.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 8.7 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 124 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -164.1 % |
| Operating Margin | -195.8 % |
| Return on Assets (ttm) | -78.5 % |
| Return on Equity (ttm) | -166 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.46 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.03 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|